The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
received:
06
12
2023
accepted:
07
06
2024
medline:
12
6
2024
pubmed:
12
6
2024
entrez:
11
6
2024
Statut:
epublish
Résumé
In recent years, the significance of detecting minimal/measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) has increased due to the availability of highly effective therapeutic agents. Flow cytometry provides notable cost-effectiveness and immediacy, with an expected sensitivity level of approximately 10
Identifiants
pubmed: 38862612
doi: 10.1038/s41598-024-64398-6
pii: 10.1038/s41598-024-64398-6
doi:
Substances chimiques
Immunoglobulin kappa-Chains
0
Immunoglobulin lambda-Chains
0
Immunoglobulin Light Chains
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13452Informations de copyright
© 2024. The Author(s).
Références
Alaggio, R. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia 36, 1720–1748. https://doi.org/10.1038/s41375-022-01620-2 (2022).
doi: 10.1038/s41375-022-01620-2
pubmed: 35732829
pmcid: 9214472
Campo, E. et al. The international consensus classification of mature lymphoid neoplasms: A report from the Clinical Advisory Committee. Blood 140, 1229–1253. https://doi.org/10.1182/blood.2022015851 (2022).
doi: 10.1182/blood.2022015851
pubmed: 35653592
pmcid: 9479027
Seymour, J. F. et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N. Engl. J. Med. 378, 1107–1120. https://doi.org/10.1056/NEJMoa1713976 (2018).
doi: 10.1056/NEJMoa1713976
pubmed: 29562156
Wierda, W. G. et al. NCCN Guidelines® Insights: Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 3.2022. J. Natl. Compr. Cancer Netw. 20, 622–634. https://doi.org/10.6004/jnccn.2022.0031 (2022).
doi: 10.6004/jnccn.2022.0031
O’Brien, S. et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 15, 48–58. https://doi.org/10.1016/s1470-2045(13)70513-8 (2014).
doi: 10.1016/s1470-2045(13)70513-8
pubmed: 24332241
Rhodes, J. M., Lopez, C. A. & Barrientos, J. C. MRD-directed therapy in CLL: Ready for prime time?. Hematology 2023, 413–420. https://doi.org/10.1182/hematology.2023000441 (2023).
doi: 10.1182/hematology.2023000441
pubmed: 38066928
Hallek, M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131, 2745–2760. https://doi.org/10.1182/blood-2017-09-806398 (2018).
doi: 10.1182/blood-2017-09-806398
pubmed: 29540348
Moreno, C. & Mora, A. MRD in CLL: some answers, many questions. Blood 138, 2746–2747. https://doi.org/10.1182/blood.2021013435 (2021).
doi: 10.1182/blood.2021013435
pubmed: 34967869
Davi, F. et al. Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing. Leukemia 34, 2545–2551. https://doi.org/10.1038/s41375-020-0923-9 (2020).
doi: 10.1038/s41375-020-0923-9
pubmed: 32561841
pmcid: 7515836
Kater, A. P. et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: Post-treatment follow-up of the MURANO phase III study. J. Clin. Oncol. 37, 269–277. https://doi.org/10.1200/jco.18.01580 (2019).
doi: 10.1200/jco.18.01580
pubmed: 30523712
Seymour, J. F. et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood 140, 839–850. https://doi.org/10.1182/blood.2021015014 (2022).
doi: 10.1182/blood.2021015014
pubmed: 35605176
pmcid: 9412011
Munir, T. et al. Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study. J. Clin. Oncol. 41, 3689–3699. https://doi.org/10.1200/jco.22.02283 (2023).
doi: 10.1200/jco.22.02283
pubmed: 37279408
pmcid: 10351955
Shanafelt, T. D. et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial. Blood 140, 112–120. https://doi.org/10.1182/blood.2021014960 (2022).
doi: 10.1182/blood.2021014960
pubmed: 35427411
pmcid: 9283968
Sharman, J. P. et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia 36, 1171–1175. https://doi.org/10.1038/s41375-021-01485-x (2022).
doi: 10.1038/s41375-021-01485-x
pubmed: 34974526
pmcid: 8979808
Munir, T. et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N. Engl. J. Med. 390, 326–337. https://doi.org/10.1056/NEJMoa2310063 (2024).
doi: 10.1056/NEJMoa2310063
pubmed: 38078508
Rawstron, A. C. et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin. Cytom. 94, 121–128. https://doi.org/10.1002/cyto.b.21595 (2018).
doi: 10.1002/cyto.b.21595
pubmed: 29024461
pmcid: 5817234
Zalcberg, I., D’Andrea, M. G., Monteiro, L., Pimenta, G. & Xisto, B. Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL-ERIC recommendations. Hematol. Transfus Cell Ther. 42, 269–274. https://doi.org/10.1016/j.htct.2019.07.006 (2020).
doi: 10.1016/j.htct.2019.07.006
pubmed: 31784406
Sorigue, M. & Junca, J. Atypical chronic lymphocytic leukemia: Brief historical overview and current usage of an equivocal concept. Int. J. Lab Hematol. 41, e17–e19. https://doi.org/10.1111/ijlh.12930 (2019).
doi: 10.1111/ijlh.12930
pubmed: 30290040
Robak, T. et al. Atypical chronic lymphocytic leukemia-the current status. Cancers 15, 4427. https://doi.org/10.3390/cancers15184427 (2023).
doi: 10.3390/cancers15184427
pubmed: 37760396
pmcid: 10527541
Sorigue, M. et al. Refining the limits of borderline lymphoproliferative disorders. Cytometry B Clin. Cytom. 96, 351–358. https://doi.org/10.1002/cyto.b.21760 (2019).
doi: 10.1002/cyto.b.21760
pubmed: 30592375
Soliman, D. S. et al. Biologic characterization of atypical chronic lymphocytic leukaemia. Int. J. Lab Hematol. 44, e49–e51. https://doi.org/10.1111/ijlh.13645 (2022).
doi: 10.1111/ijlh.13645
pubmed: 34224207
Sorigue, M., Junca, J. & Zamora, L. New biological insights into atypical chronic lymphocytic leukemia. Int. J. Lab Hematol. 44, e8–e9. https://doi.org/10.1111/ijlh.13647 (2022).
doi: 10.1111/ijlh.13647
pubmed: 34218524
Köhnke, T. et al. Diagnosis of CLL revisited: Increased specificity by a modified five-marker scoring system including CD200. Br. J. Haematol. 179, 480–487. https://doi.org/10.1111/bjh.14901 (2017).
doi: 10.1111/bjh.14901
pubmed: 28832948
Tamura, K. et al. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol. 67, 152–157. https://doi.org/10.1034/j.1600-0609.2001.5790514.x (2001).
doi: 10.1034/j.1600-0609.2001.5790514.x
pubmed: 11737247
Yang, S. M., Li, J. Y., Gale, R. P. & Huang, X. J. The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?. Blood Rev. 29, 205–213. https://doi.org/10.1016/j.blre.2014.12.001 (2015).
doi: 10.1016/j.blre.2014.12.001
pubmed: 25541495
Oscier, D. G. et al. Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12. Br. J. Haematol. 98, 934–939. https://doi.org/10.1046/j.1365-2141.1997.3263141.x (1997).
doi: 10.1046/j.1365-2141.1997.3263141.x
pubmed: 9326192
Rawstron, A. C. et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: An European Research Initiative on CLL study. Leukemia 30, 929–936. https://doi.org/10.1038/leu.2015.313 (2016).
doi: 10.1038/leu.2015.313
pubmed: 26639181
pmcid: 4832072
Lee, H. et al. Nationwide statistical analysis of lymphoid malignancies in Korea. Cancer Res. Treat. 50, 222–238. https://doi.org/10.4143/crt.2017.093 (2018).
doi: 10.4143/crt.2017.093
pubmed: 28361523
Ren, W., Li, W., Ye, X., Liu, H. & Pan-Hammarström, Q. Distinct subtype distribution and somatic mutation spectrum of lymphomas in East Asia. Curr. Opin. Hematol. 24, 367–376. https://doi.org/10.1097/moh.0000000000000355 (2017).
doi: 10.1097/moh.0000000000000355
pubmed: 28406802
Li, Y. et al. A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia. Cancer Med. 10, 4387–4396. https://doi.org/10.1002/cam4.3983 (2021).
doi: 10.1002/cam4.3983
pubmed: 34061467
pmcid: 8267114
Walewska, R. et al. Guideline for the treatment of chronic lymphocytic leukaemia. Br. J. Haematol. 197, 544–557. https://doi.org/10.1111/bjh.18075 (2022).
doi: 10.1111/bjh.18075
pubmed: 35313007
Wierda, W. G. et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 18, 185–217. https://doi.org/10.6004/jnccn.2020.0006 (2020).
doi: 10.6004/jnccn.2020.0006
Baskar, S. et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 14, 396–404. https://doi.org/10.1158/1078-0432.Ccr-07-1823 (2008).
doi: 10.1158/1078-0432.Ccr-07-1823
pubmed: 18223214
Matutes, E. et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8, 1640–1645 (1994).
pubmed: 7523797
Lesesve, J. F. et al. Combination of CD160 and CD200 as a useful tool for differential diagnosis between chronic lymphocytic leukemia and other mature B-cell neoplasms. Int. J. Lab Hematol. 37, 486–494. https://doi.org/10.1111/ijlh.12315 (2015).
doi: 10.1111/ijlh.12315
pubmed: 25470765
Soliman, D. S. et al. Downregulation of Lymphoid enhancer-binding factor 1 (LEF-1) expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features. Int. J. Lab Hematol. 43, 515–525. https://doi.org/10.1111/ijlh.13420 (2021).
doi: 10.1111/ijlh.13420
pubmed: 33314668
Moreau, E. J. et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am. J. Clin. Pathol. 108, 378–382. https://doi.org/10.1093/ajcp/108.4.378 (1997).
doi: 10.1093/ajcp/108.4.378
pubmed: 9322589
Goshaw, J. M., Gao, Q., Wardrope, J., Dogan, A. & Roshal, M. 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL. Cytometry B Clin. Cytom. 100, 509–518. https://doi.org/10.1002/cyto.b.21953 (2021).
doi: 10.1002/cyto.b.21953
pubmed: 32896973